About the Nonprofit
Visit Our Website
Since being founded in 2009 by a patient facing cholangiocarcinoma, TargetCancer Foundation (TCF) has stood at the intersection of rare cancer patients, advocates, researchers, and clinicians. TCF is expanding its impact through TCF-001 TRACK, a prospective clinical trial seeking to enroll 400 patients with rare cancers or cancer of unknown primary. While we can quantify the number of individuals enrolled in our clinical trial and attending our scientific meetings, the broader impact of our research funding is impossible to quantify as it has the potential to impact thousands of patients facing rare cancers.
TRACK provides participating rare cancer patients and their physicians with personalized, actionable information to potentially inform treatment, as well as recommendations for on-label, off-label, or clinical trial treatments from an expert panel of rare cancer clinicians and scientists. Simultaneously, TRACK generates critical genomic data to drive a better understanding of often overlooked rare cancers. Through a remote consenting process, patients can fully consent and enroll in the TRACK study from their home, and without traveling to a clinical trial site.
TargetCancer Foundation has awarded over $1 million dollars in funding for research into rare cancers. In 2020, we launched a patient-driven precision medicine clinical trial exclusively forrare cancer patients. Despite the many challenges posed by the global pandemic, we continue to assist rare cancer patients by providing a community of support, clinical trial guidance, and initiatives that allow patientsto directly participate in rare cancer research.